dasiglucagon · Zegalogue
Peptide
Evidence outlook
Approved: Severe Hypoglycemia
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.
Also approved (1)
- Zegalogue is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 6 years and over with diabetes mellitus.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03895697 NCT03895697 · Hypoglycemia, Diabetes Mellitus, Type 1 The trial randomized 92 participants and masked participants, care providers, investigators, and outcome assessors while comparing two dasiglucagon batches in a crossover design. Its primary measure was a physiological glucose-recovery endpoint rather than a hard clinical outcome, and no primary endpoint result is posted. Registry: NCT03895697 | 3 | Time to plasma glucose recovery (0-45 minutes after dosing) 2019-07-30 | Results not posted; external-source review pending | Partial signal | link ↗ |
View 3 more trials
NCT03378635 NCT03378635 · Severe Hypoglycemia in Type 1 Diabetes Adults with type 1 diabetes were randomly assigned in a quadruple-blind trial to dasiglucagon, placebo, or GlucaGen, with 170 participants randomized and 168 receiving treatment. The primary clinical endpoint was met: median time to plasma glucose recovery was 10 minutes with dasiglucagon versus 40 minutes with placebo (p<0.001). Registry: NCT03378635 | 3 | Time to Plasma Glucose Recovery (0-45 minutes after dosing) 2018-04-27 | Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) | Reliable signal | link ↗ |
NCT03688711 NCT03688711 · Hypoglycemia The trial was randomized, quadruple-blind, and placebo-controlled, with 34 participants receiving dasiglucagon and 10 receiving placebo; its objective primary endpoint was significantly favorable for dasiglucagon. However, no power calculation was reported in the available sources, so the study cannot be considered adequately powered for the highest evidence grade. Registry: NCT03688711 | 3 | Time to Plasma Glucose Recovery. (0-45 minutes after dosing) 2019-03-11 | Time to Plasma Glucose Recovery. (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 35 minutes | Partial signal | link ↗ |
NCT03667053 NCT03667053 · Hypoglycemia The trial was randomized and quadruple-blind, included placebo and active-controlled groups, and enrolled 42 participants (41 treated). Its objective primary endpoint, time to plasma glucose recovery, was significantly better with dasiglucagon than placebo, but no primary-endpoint power or sample-size calculation is reported in the available sources, limiting the strength of the evidence. Registry: NCT03667053 | 3 | Time to Plasma Glucose Recovery (0-45 minutes after dosing) 2019-06-28 | Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12) | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (9)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (4)
What this study did
What this study did
What this study did
What this study did
Competitive landscape
Other Glucagon receptor (agonist) drugs
Nasal Glucagon. Compare all 2 Glucagon receptor (agonist) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Severe Hypoglycemia: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Dasiglucagon (Zegalogue): this drug | Approved | Peptide | Glucagon receptor (agonist) | Partial signal | NCT03378635: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 10 to 10) | Placebo 40 minutes (95% CI 30 to 40) | GlucaGen® 1.0 mg 12 minutes (95% CI 10 to 12) NCT03667053: Time to Plasma Glucose Recovery (0-45 minutes after dosing): Dasiglucagon 0.6 mg 10 minutes (95% CI 8 to 12) | Placebo 30 minutes (95% CI 20 to 45) | GlucaGen® 1.0 mg 10 minutes (95% CI 8 to 12) | |
| Nasal Glucagon (Baqsimi) | Approved | Peptide | Glucagon receptor (agonist) | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
Upcoming events
No upcoming readouts on record for this asset.